Find a Provider

Corey J. Langer, MD Physician

Director, Thoracic Oncology
Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Langer is a Penn Medicine employed physician.

About Dr. C Langer

Recognized annually in Philadelphia Magazine's Top Docs issue from 2009 through 2015

Recognized by America's Top Doctors, 2008, 2010-14

Recognized by Best Doctors in America 2009-2010, 2013-2014

Clinical Specialties

Specialties:

  • Medicine
    • Medical Oncology

Programs & Services:

  • Cancer
    • Lung Cancer
    • Oropharyngeal Cancer
    • Pituitary Cancer
    • Thymus Cancer
  • Lung
    • Mesothelioma & Pleural Disease

Board Certification:

  • Hematology, 1986
  • Internal Medicine, 1984
  • Medical Oncology, 1987

Conditions & Treatments:

  • Lung Cancer
  • Lung Carcinoid Tumor
  • Mesothelioma
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • thoracic malignancies
  • Thyroid Cancer

Practice Locations and Appointments

  • Lung Cancer

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 2nd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

  • Head and Neck Oncology

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 2nd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Boston University School of Medicine
Residency: Graduate Hospital
Fellowship: Penn Presbyterian Medical Center
Fellowship: Fox Chase Cancer Center

Memberships

American Association for Cancer Research, (Member), National American College of Physicians, National American College of Surgeons Head and Neck Database Committee, National American Society of Clinical Oncology, National BMS Advisory Board on Ipilimumab, National Eastern Cooperative Oncology Group (ECOG), Chair of Aging Subcommittee of the Outcomes Committee, National Geriatric Oncology Consortium (GOC), Member Scientific Advisors Board, National Geriatric Oncology Consortium (GOC), National International Association for Study of Lung Cancer, International Lung Cancer Partnership, Local National Comprehensive Cancer Network Non-Small Cell Lung Cancer Panel, National National Comprehensive Cancer Network Small Cell Lung Cancer Panel, National Oncology Physician Network (OPN), Inc., Philadelphia, Local Ortho Advisory Board, National Pennsylvania Medical Society, Local Pharmacyclics Advisory Board, National Program Committee of the International Association of Lung Cancer, International

Affiliation

Dr. Langer is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Movsas B, Scott C, Curran Jr W, Byardt R and Langer C.: A Quality-Adjusted Time Without Symptoms or Toxicity (QTWiST) Analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol (ASCO), San Francisco, CA, J Clin Oncol, in press. : 2008.

Schnoll RA, James C, Malstrom M, Rothman R, Wang H, Babb J, Miller SM, Ridge JA, Movsas B, Langer C, Unger M, Goldberg M: Longitudinal predictors of continued tobacco use among patients diagnosed with cancer. Annals of Behavioral Medicine, in press : 2008.

Langer, CJ Stephenson, P, Schiller J, Harrington D, Sandler A, Belani, C, Johnson D: The Role of Combination Platinum-Based Treatment in the Elderly: Lessons from ECOG 1594 Clinical Lung Cancer, Cancer Conference Highlights, in press : 2008.

Janne PA, Simon GR, Langer CJ, Taub RN, Dowlati, A, Fidias F, Obasaju C, Monberg M, Kindler HA: Phase II Trial of Pemetrexed and Gemcitabine in Chemotherapy Naïve Malignant Pleural Mesothelioma J Clin Oncol, in press : 2008.

Konski A; Bhargavan M; Owen J, Komaki R, Langer C, Byhardt R; Paulus R, Choy H, Bruner D, Curran W: Less is not always more; An Economic Analysis of Radiatoin Therapy Oncology Group 9410 Poster 1080, American Society of Therapeutic Radiation Oncology, Los Angeles, CA : 2007.

Movsas B; Moughan J; Sarna L; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Wasserman T; Bruner D;: Quality of Life (QoL) supercedes the classic predictors of survival in locally advanced non-small cel l lung cancer: An analysis of Radiation Therpay Oncology Group (RTOG) 9801 Oral presentation. American Society of Therapeutic Radiation Oncology, Los Angeles, CA : 2007.

Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K: Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol.20;25(30):4800-5 : 2007.

Wakelee HA, Dahlberg SE, Schiller JH, Langer CJ, Sandler AB, Brahmer JR, Belani CP: Menopausal status of women may affect survival in advanced NSCLC: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies using age of 60 years or older as a surrogate marker. Journal of Thoracic Oncology, Vol 2, No 8, Supplement 4, S570, P1-052 : 2007.

Langer CJ, Paulus R, Curran W, Movsas B Werner-Wasik M, Komaki R, Lee JS, Choy H: Rethinking prognostic factors in the era of combined modality therapy for locally advanced non-small cell lung cancer (LA-NSCLC): a retrospective analysis of RTOG Protocols 9410 and 9801. Journal of Thoracic Oncology, Vol 2, No 8, Supplement 4, S309 A1-03 : 2007.

Movsas B, Langer C, Wang LH, Jotte R, Xu F, Huang C, Monberg M, Obasaju CK: Phase 2 trial of cisplatin, etoposide, and radiation followed by gemcitabine vs gemcitabine and docetaxel in stage IIIA/B unresectable non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology, Vol 2, No 8, Supplement 4, S648, P2-195 : 2007.

Academic Contact Info

Perelman Center for Advanced Medicine
2 West Pavilion
3400 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 615-5121
Fax: (215) 615-5122
Patient appointments: 800-789-PENN (7366)

Related Links